Evaluation ofIL-6 and TGF- β1level in serum and saliva of patients with systemic sclerosis

Abstract

Introduction and purpose: Systemic sclerosis (SSc) is multi organs disorder with hyper reactive immune system reflected by excessive skin sclerosis and affected organs. Cytokines were release as basic procedures in SSc pathogenesis as they are convolute in T and B cell activation leading to inflammation, auto antibodies, and microvascular injury this entire event leading to fibrosis.This study is designed to investigate the changes of IL6 and Transforming growth factor beta 1 (TGF-β1) in the whole saliva and serum of patient with SSc. Study design: forty female systemic sclerosis patient diagnosed previously by Rheumatologist in Bagdad teaching hospital in Bagdad cityfrom 2015-2016, serum and saliva werecollect, IL-6 and TGF-B1were investigate and statistical data compared with control subjects. Method: The quantitative determination of TGF-β1was used from Elabscience Company, quantitative determination of human TGF-β1 concentrations in serum, plasma and other biological fluids by ELISA technique. The quantitative determination of IL-6was used from Elabscience Company that it was determined of human IL6 concentrations in serum, plasma and other biological fluids by ELISA technique. Results: The present study showed that the median and mean rank level of serum IL-6 in SSc patients (18.27 and 55.93) was highly significantly increased (P<0.001) as well as the mean level ofsalivary IL-6 in SSc patients (7.084 ± 1. 984) was highly significantly increased (P<0.001) than that the control subjects.The median and mean rank level of serum and salivary TGF- β1 in SSc patient was highly significantly increased (P<0.001) than control subject. Conclusion: IL-6 and TGF- β1play a major role in SSc pathogenesis therefore both biomarker were investigate in serum and saliva ofSSc patients, saliva is non-invasive and accurate in detection ofthese markers.